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Strategic Partnering to Evaluate Cancer Signatures
The National Cancer Institute (NCI) invites investiga-
tors to form strategic partnerships that will bring
together the multidisciplinary expertise and resources
needed to determine how the information derived
from comprehensive molecular analyses can be used to
improve patient care and, ultimately, patient outcomes.
The purpose of this request for applications (RFA) is to
build on recent demonstrations that molecular signa-
tures correlate with important clinical parameters in
cancer. Applicants are asked to propose evaluation of
potential clinical usefulness of molecular signatures
already developed using a variety of molecular analysis
technologies including DNA-, RNA-, or protein-based
technologies. 
Retrospective studies have shown that molecular
signatures have identiﬁed subgroups of patients whose
tumors are histopathologically the same but who have
different clinical outcomes. The challenge is to trans-
late the information in these molecular signatures into
tools that can be used in clinical decision making. To
meet this challenge, signatures must be conﬁrmed in
independent studies. Critical elements of signatures
that correlate most strongly with the clinical end point
of interest must be identiﬁed and conﬁrmed. Robust
assays feasible for use in the clinical setting must be
developed and validated. 
This open competition will provide the cancer
research community the opportunity to establish col-
laborations focused on the translation of promising
molecular profiles toward clinical applications. The
NCI will continue the policy of requiring public release
in a timely fashion of the rich data sets generated dur-
ing these projects. Access to these data sets will beneﬁt
the entire cancer research community. This initiative
will help ensure that the NCI goal of eliminating the
suffering and death from cancer by 2015 is met.
The ability of molecular proﬁles to provide useful
clinical information is being demonstrated in many
projects throughout the cancer research community
and must be evaluated further. Scientists are discover-
ing molecular signatures by analysis of gene expression
at the RNA level, gene expression following protein
translation, gene mutations, DNA deletions, DNA
ampliﬁcations, epigenetic changes of DNA, and post-
translational modiﬁcation of proteins. The challenge is
to move beyond the initial discovery of potentially use-
ful proﬁles, to decide what subset of the elements in
the proﬁles needs to be measured, to conﬁrm that the
proﬁles are robust and can be reproducibly measured,
and to evaluate the clinical utility of the proﬁles.
This RFA is intended to support projects carrying
out the extensive research needed to bridge the gap
between discovery of molecular proﬁles and their inte-
gration into clinical decision making. Collaborations
must be established to provide all of the expertise and
clinical resources required to achieve proposed project
goals. It is anticipated that these will be multi-institu-
tional projects involving investigators with expertise in
technology development and application, cancer biol-
ogy, oncology, pathology, clinical cancer research, bio-
statistics, bioinformatics, and, possibly, biomedical
imaging. 
Applicants must propose projects that build on
previously identiﬁed molecular proﬁles. Applications
proposing only proﬁle discovery or technology devel-
opment projects will not be considered responsive to
this RFA. The proposed studies should be designed to
conﬁrm and reﬁne signatures that have been demon-
strated to provide information that is potentially useful
clinically and that may be used to aid in making clini-
cal decisions. 
Applicants may propose to deﬁne critical compo-
nents in the signature, to confirm that the selected
components continue to provide the desired clinical
information, and to develop robust assays for measur-
ing those components. They may continue to develop
and/or modify analytical technologies and algorithms
for data analysis required to meet the goals of the pro-
posed projects. 
Applicants should propose projects that address
clinical issues or needs in a speciﬁc cancer or a closely
related set of cancers or in a group of patients whose
cancers have related molecular alterations. Applicants
must describe the clinical question(s) or need(s) they
plan to address. Examples of questions of interest may
include, but are not limited to, risk of progression in
early-stage disease, prognosis at the time of diagnosis,
identiﬁcation of subsets within a tumor stage or grade
where there is known heterogeneity in clinical behavior
including differential response to standard therapies
and/or radiation response, and selection of appropriate
patients for or prediction of response to selected or tar-
geted therapies. Applicants should not propose projects
addressing early detection of cancer in asymptomatic or
high-risk populations or risk of progression of prema-
lignant lesions. 
Applicants may propose the use of a variety of
analytical platforms. Applicants may evaluate signa-
tures that have previously been identiﬁed using analyti-
cal technologies such as gene expression microarrays,
SAGE, multiplex PCR, or any of a large number of
protein analysis technologies. Genomic analysis tech-
nologies such as array CGH, comprehensive muta-
tional analysis technologies, SNP analysis, and analysis
of epigenetic events are also appropriate. Applicants
must demonstrate that they have experience with the
analytical technologies that will be used in the project
and demonstrate that the technologies can be used for
analysis of standard pathological specimens. Applicants
are encouraged to propose the use of multiple analyti-
cal strategies. The integration of data to build clinically
useful proﬁles that can be measured reproducibly in a
clinical setting must be the focus of the project, no
matter which technologies or analytic platforms are
proposed.
The conﬁrmation, reﬁnement, and evaluation of
clinically useful molecular profiles and the develop-
ment of robust clinical assays are the primary goals of
this initiative. Clinical utility of the signatures and per-
formance of the clinical assays in the context of their
intended clinical use must be validated before they can
be integrated into clinical practice. Final validation of
the proﬁles in a clinical trial setting is beyond the scope
of this RFA. However, it is anticipated that some of the
projects may be ready to move proﬁles into clinical tri-
als as early as the midpoint of the project period. NCI
staff will facilitate collaborations between the projects
funded on this initiative and other clinical resources
and clinical trials activities supported by the NCI.
Applicants must justify the numbers of specimens
to be analyzed based on appropriate statistical designs
for the proposed studies. Applicants must have estab-
lished collaborations to ensure availability of the clini-
cal materials required. The availability of tissue
resources with appropriate clinical annotation is critical
to the successful completion of the projects. Experience
has demonstrated that the dimensionality of the molec-
ular proﬁling data requires the analysis of hundreds of
specimens to get statistically significant results.
Applicants may propose to obtain tissues from a previ-
ous collection or prospectively, as long as the speciﬁc
aims proposed can be accomplished within the period
of the grant award. 
Applicants should request sufﬁcient resources for
their bioinformatics staff to be able to provide an
appropriate interface with the NCI Center for
Bioinformatics. Sharing of the data between projects
where appropriate and public release of data after pub-
lication will be a requirement for this initiative.
Awardees will retain primary rights to the data devel-
oped under these awards, subject to government rights
of access consistent with current DHHS, PHS, and
NIH policies. 
This RFA uses just-in-time concepts. It also uses
the nonmodular budgeting formats. Follow the
instructions for nonmodular budget research grant
applications. This program does not require cost shar-
ing as defined in the current NIH Grants Policy
Statement at http://grants.nih.gov/grants/policy/
nihgps_2001/part_i_1.htm. 
This RFA will use the NIH cooperative agreement
(U01) award mechanism. Applicants are solely respon-
sible for planning, directing, and executing the pro-
posed project. This RFA is a one-time solicitation.
Applications that are not funded in the competition
described in this RFA may be resubmitted as new
investigator-initiated applications using the standard
receipt dates for new applications described in the
instructions to the PHS 398 application.
The NCI intends to commit approximately $10
million in ﬁscal year 2004 to fund 3–4 new grants in
response to this RFA, contingent upon the availability
of funds and the receipt of a sufﬁcient number of meri-
torious applications. An applicant may request a pro-
ject period of up to 5 years and a budget for total direct
costs of up to $2.5 million per year. Because the nature
and scope of the proposed research will vary from
application to application, it is anticipated that the size
and duration of each award will also vary. Applicant
institutions may be for-proﬁt or nonproﬁt organiza-
tions; public or private institutions, such as universities,
colleges, hospitals, and laboratories; units of state and
local governments; eligible agencies of the federal gov-
ernment; or domestic or foreign institutions/organiza-
tions. Any individual with the skills, knowledge, and
resources necessary to carry out the proposed research
is invited to work with his/her institution to develop an
application for support. Individuals from underrepre-
sented racial and ethnic groups as well as individuals
with disabilities are always encouraged to apply for
NIH programs.
In order to ensure maximum progress in the pro-
jects funded by this initiative and to maximize progress
toward the NCI 2015 goals, several special activities
will be required of funded investigators. An annual
meeting of all funded investigators will be held to share
progress and research insights that may beneﬁt all of
the projects. The annual scientiﬁc meeting will be initi-
ated after the ﬁrst year of funding. Other focused meet-
ings will be held each year to address arising issues or to
take advantage of special scientific opportunities.
Applicants should request travel funds in their budgets
for key personnel to attend two meetings per year. 
Funded investigators will be asked to work
together on issues common to all funded projects.
Although each applicant will propose an independent
project, all applicants are expected to face many of the
same challenges and will beneﬁt from the experiences
of and interactions with the other funded investigators.
The interactions of funded groups will be overseen by a
steering committee made up of two investigators, the
principal investigator, one additional investigator from
each funded project, and appropriate NCI staff.
Applicants should state in their applications their com-
mitment to participating on the steering committee
and in interactions among the funded groups.
When proposed studies involve collection of
human samples, specimens and/or clinical data, investi-
gators should consult the NIH brochure titled Research
on Human Specimens: Are You Conducting Research
Using Human Subjects? (http://www-cdp.ims.
nci.nih.gov/policy.html) and in the OHRP guidance
on repositories, tissue storage activities, and data banks
(http://ohrp.osophs.dhhs.gov/g-topicstest.htm) to
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Applicants must describe how they intend to meet
NIH policies for sharing of data or why data sharing is
not possible. In this regard, attention is drawn to the
NIH Final Statement on Sharing Research Data
(http://grants.nih.gov/grants/policy/data_sharing/index
.htm and http://grants.nih.gov/grants/guide/
notice-ﬁles/NOT-OD-03-032.html), which was pub-
lished in the NIH Guide on 26 February 2003 (“Data
Sharing Guidelines”). 
A meeting of interested investigators will be held
14 May 2004 in the Natcher Conference Center at
NIH, Bethesda, Maryland. The meeting is intended to
answer questions potential applicants may have about
the intent of the initiative. Prospective applicants are
asked to submit a nonbinding letter of intent by 22
June 2004. The anticipated award date is 1 April 2005. 
Applications must be prepared using the PHS 398
research grant application instructions and forms (rev.
5/2001). Applications must have a Dun and Bradstreet
Data Universal Numbering System (DUNS) number
as the Universal Identiﬁer when applying for federal
grants or cooperative agreements. The DUNS number
can be obtained by calling 1-866-705-5711 or through
the website at http://www.dunandbradstreet.com/.
The PHS 398 document is available at http://grants.
nih.gov/grants/funding/phs398/phs398.
html in an interactive format. For further assistance,
contact GrantsInfo, 301-435-0714, e-mail:
GrantsInfo@nih.gov. 
Contact: James W. Jacobson, Division of Cancer
Treatment and Diagnosis, NCI, 6130 Executive Blvd,
EPN Rm 6035A, Bethesda, MD 20892 USA, 301-
402-4185, fax: 301-402-7819, e-mail: jacobsoj@
mail.nih.gov. Reference: RFA No. RFA-CA-04-015
Revolutionary Genome Sequencing Technologies:
The $1,000 Genome 
The purpose of this request for applications (RFA) is
to solicit grant applications to develop novel tech-
nologies that will enable extremely low-cost genomic
DNA sequencing. Current technologies are able to
produce the sequence of a mammalian-sized genome
of the desired data quality for $10–50 million; the
goal of this initiative is to reduce costs by at least 4
orders of magnitude, so that a mammalian-sized
genome could be sequenced for approximately
$1,000. Substantial fundamental research is needed
to develop the scientiﬁc and technological knowledge
underpinning such a major advance. Therefore, it is
anticipated that the realization of the goals of this
RFA is a long-range effort that is likely to require as
much as 10 years to achieve. The parallel RFA HG-
04-002 (details at http://grants.nih.gov/grants/
guide/rfa-files/RFA-HG-04-002.html) solicits grant
applications to develop technologies to meet the
shorter-term goal of achieving a 2 orders of magni-
tude cost reduction in about 5 years.
The ability to sequence complete genomes and
the free dissemination of the sequence data have dra-
matically changed the nature of biological and bio-
medical research. Sequence and other genomic data
have the potential to lead to remarkable improve-
ments in many facets of human life and society,
including the understanding, diagnosis, treatment,
and prevention of disease; advances in agriculture,
environmental science, and remediation; and the
understanding of evolution and ecological systems.
At current prices, the cost of sequencing a mam-
malian-sized genome means we must still be very
selective when choosing new genomes to sequence.
In particular, we remain very far away from being
able to afford to use comprehensive genomic
sequence information in individual health care. For
this and many other reasons, the rationale for achiev-
ing the ability to sequence entire genomes very inex-
pensively is very strong.
Given the broad utility and high importance of
dramatically reducing DNA sequencing costs, the
National Human Genome Research Institute
(NHGRI) is launching two parallel technology
development programs. For both programs, the cost
targets are defined in terms of a mammalian-sized
genome, about 3 gigabases (Gb), with a target
sequence quality equivalent to, or better than, that of
the mouse assembly published in December 2002
[Nature 420:520 (2002)].
The ultimate goal of this program is to obtain
technologies that can produce an assembled
sequence (i.e., de novo sequencing). However, an
accompanying shorter-term goal is to obtain highly
accurate sequence data at the single base level, i.e.,
without assembly information, that can be overlaid
onto a reference sequence for the same organism
(i.e., resequencing). This could be achieved, for
example, with short reads that have no substantial
information linking them to other reads. While the
sequence product of this kind of technology would
lack some important information, such as informa-
tion about genomic rearrangements, it would never-
theless potentially be available more rapidly and
produce data of great value for certain uses in study-
ing disease etiology and in individualized medicine.
Therefore, both programs’ objectives include a bal-
anced portfolio of projects developing both de novo
and resequencing technologies.
The goal of research supported under this RFA
is to develop new or improved technology to enable
rapid, efficient genomic DNA sequencing. New
sensing and detection modalities will likely be
needed to achieve these goals. New fabrication tech-
nologies may also be required. It is therefore antici-
pated that proposals responding to this RFA will
need to involve fundamental and engineering
research conducted by multidisciplinary teams of
investigators. The guidance for budget requests
accommodates the formation of groups having inves-
tigators at several institutions, in cases where that is
needed to assemble a team of the appropriate bal-
ance, breadth, and experience.
Although the ultimate goal is to develop full-
scale sequencing systems, independent research on
essential components will also be considered respon-
sive to this RFA. However, it will be important for
applicants proposing research on system components
or concepts to describe how the knowledge gained as
a result of their project would be incorporated into a
full system that they might subsequently propose to
develop, or that is being developed by other groups.
Such independent proposals are an important path
for pursuing novel high-risk/high-payoff ideas.
Research conducted under this RFA may
include development of the computational tools
associated with the technology, e.g., to extract
sequence information, including signal processing,
and to evaluate sequence quality and assign confi-
dence scores. It may also address strategies to assem-
ble the sequence from the information being
obtained from the technology or by merging the
sequence data with information from parallel tech-
nology. However, this RFA will not support devel-
opment of sequence assembly software independent
of technology development to obtain the sequence.
The quality of sequence to be generated by the
technology is of paramount importance for this
solicitation. Two major factors contributing to
genomic sequence quality are per-base accuracy and
contiguity of the assembly. Much of the utility of
comparative sequence information will derive from
characterization of sequence variation between
species, and between individuals of a species.
Therefore, per-base accuracy must be high enough
to distinguish polymorphism at the single-nucleotide
level (substitutions, insertions, deletions). Experience
and resulting policy have established a target accu-
racy of not more than 1 error per 10,000 bases. All
applications in response to this RFA, whether to
develop resequencing or de novo sequencing tech-
nologies, must propose achieving per-base quality at
least to this standard.
The NHGRI intends to commit approximately
$6 million in fiscal year 2004 to fund 3–10 new
and/or competitive continuation grants in response
to this RFA, and an additional $5 million in fiscal
year 2005. For the R21 mechanism, an applicant
may request a project period of up to 3 years and a
budget of up to $200,000 in direct costs per year.
For R21/R33 applications, the total project period
may not exceed 5 years, distributed as required for
the project; the R21 phase may request a budget up
to $200,000 in direct costs and the R33 phase up to
$2 million in direct costs per year. For R01 and P01
mechanisms, an applicant may request a project
period of up to 5 years and a budget of up to $2 mil-
lion in direct costs per year. Budgets may exceed this
guidance only to accommodate indirect costs to sub-
contracts. Applicants should be aware that the
NHGRI intends to fund as many promising pro-
jects, of varying scope, as possible in order to pursue
multiple approaches to solving these difficult prob-
lems and mitigate risk. Therefore, awards may not
be made at the maximum budget level. 
Applicant institutions may be for-proﬁt or non-
proﬁt organizations; public or private institutions, such
as universities, colleges, hospitals, and laboratories;
units of state and local governments; eligible agencies
of the federal government; or domestic or foreign insti-
tutions/organizations. Any individual with the skills,
knowledge, and resources necessary to carry out the
proposed research is invited to work with his/her insti-
tution to develop an application for support.
Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
Applications must be prepared using the PHS 398
research grant application instructions and forms (rev.
5/2001). Applications must have a Dun and Bradstreet
Data Universal Numbering System (DUNS) number
as the Universal Identiﬁer when applying for federal
grants or cooperative agreements. The DUNS number
can be obtained by calling 1-866-705-5711 or through
the website at http://www.dunandbradstreet.com/.
The PHS 398 document is available at http://grants.
nih.gov/grants/funding/phs398/phs398.
html in an interactive format. For further assistance,
contact GrantsInfo, 301-435-0714, e-mail:
GrantsInfo@nih.gov. 
Letters of intent must be received by 15 March
2004 or 14 September 2004. Applications are due 15
April 2004 or 14 October 2004. The earliest antici-
pated start date is 30 September 2004 or 1 June 2005.
Contact: Jeffery A. Schloss, Ph.D. Division of
Extramural Research, NHGRI, Bldg 31, Rm B2B07,
Bethesda, MD 20892-2033 USA, 301-496-7531, fax:
301-480-2770, e-mail: jeff_schloss@nih.gov.
Reference: RFA No. RFA-HG-04-003
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